Inhaled iloprost as third add-on therapy in idiopathic pulmonary arterial hypertension

Caio J C S Fernandes; Taysa A F da Silva; Jose L Alves Jr; Carlos V P Jardim; Rogerio de Souza

doi:10.1177/2045894020981350

Inhaled iloprost as third add-on therapy in idiopathic pulmonary arterial hypertension

Pulm Circ. 2021 Jan 20;11(1):2045894020981350. doi: 10.1177/2045894020981350. eCollection 2021 Jan-Mar.

Authors

Caio J C S Fernandes^{1

2

3}, Taysa A F da Silva¹, Jose L Alves Jr^{1

2

3}, Carlos V P Jardim^{1

3}, Rogerio de Souza^{1

3}

Affiliations

¹ Pulmonary Circulation Unity, Cardiopulmonology Department, Heart Institute, University of Sao Paulo Medical School, Sao Paulo, Brazil.
² Cancer Institute, University of Sao Paulo Medical School, São Paulo, Brazil.
³ Sirio Libanes Hospital, São Paulo, Brazil.

Abstract

Triple combination therapy is suggested in current pulmonary arterial hypertension guidelines in case of unsatisfactory treatment with oral double combination therapy. However, there is a lack of evidence concerning some of the drug combinations currently employed. We demonstrate the clinical and hemodynamical benefits of inhaled iloprost as third add-on therapy in idiopathic pulmonary arterial hypertension.

Keywords: hemodynamics; inhaled iloprost; pulmonary arterial hypertension; sequential triple combination therapy.